HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
263 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2024-10-10 (openpr.com)
Ivacaftor API Market to Set an Explosive Growth in Near Future | Cipla, Mylan N.V., Hetero Drugs Limited
Press release - Infinity Business Insights - Ivacaftor API Market to Set an Explosive Growth in Near Future | Cipla, Mylan N.V., Hetero Drugs Limited - published on openPR.com
Read more
2020-06-21 (reuters.com)
India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug
India's drug regulator has given Hetero Labs and Cipla Ltd <CIPL.NS> the green light to manufacture and market their generic version of Gilead Sciences Inc's <GILD.O> experimental COVID-19 treatment remdesivir, the Indian pharmaceutical companies said on Sunday.
Read more
2020-06-21 (businesstoday.in)
Coronavirus drug update: Cipla, Hetero to launch Remdesivir at Rs 3,000-6,000
Cipla plans to launch the drug in a couple of days, while Hetero's drug is expected to hit the market in a week
Read more
2011-01-29 (newindianexpress.com)
Hetero, Matrix sign deal with Irish firm
HYDERABAD: Two city-based pharmaceutical companies — Hetero Drugs and Matrix Labs — have obtained the licensing, manufacturing and commercialisation rights to manufacture and market Rilpivirin
Read more
(indiatimes.com)
Sun Pharma, Hetero recall drugs in the US market, Health News, ET HealthWorld
Hetero: As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The Indian pharmaceutical industry is the world's third-largest by volume and 14th-largest in terms of value. India exported pharmaceuticals worth Rs 1,75,040 crore in the financial year 2021-22, including bulk drugs/ drug intermediates.
Read more
(economictimes.com)
Sun Pharma, Hetero recall drugs in US market
As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Read more